As part of the agreement, RTI Surgical has acquired Exactech's Optecure, a 510(k)- cleared demineralized bone matrix for use as a bone graft extender in the spine, pelvis, and extremities
RTI Surgical and Exactech Announce Strategic Partnership. (Credit: PRNewswire / RTI Surgical)
RTI Surgical, a leading surgical implant company providing blue-chip OEM customers with a portfolio of tissue-based, synthetic and metal implants, has today announced it has entered in a long-term strategic agreement with leading global medical device OEM Exactech, related to the development and supply of biologic bone substitutes.
As part of the agreement, RTI Surgical has acquired Exactech’s Optecure®, a 510(k)- cleared demineralized bone matrix for use as a bone graft extender in the spine, pelvis, and extremities. Optecure® will complement RTI Surgical’s market-leading portfolio of bone graft substitutes.
“Biologic materials that support joint replacement surgery are an important facet of Exactech’s business,” said Exactech CEO Darin Johnson. “This collaboration with RTI allows each company to focus on our unique strengths. RTI has specialized expertise in the procurement, processing and manufacturing of human-derived tissue-based implants and Exactech markets and distributes the clinical solutions to help surgeons treat patients. We are pleased that this deal strengthens our long-standing partnership and positions us to have a more stable supply to support our selling efforts.”
“Having a partner like Exactech trust us to become a preferred supplier for their bone graft portfolio is a key milestone in our journey to become the market leading private-label implant supplier to OEMs. Growing our partnership with Exactech and developing Optecure® enables us to achieve our vision of enhancing the gifts of life, and we thank the Exactech team for this partnership,” said RTI Surgical CEO Olivier Visa.
Optecure® is RTI Surgical’s first product acquisition since the company was acquired by Montagu in 2020.
Source: Company Press Release